618
Disease Control
Vaccine Development Atlantic salmon, which were vaccinated i.p. with an adjuvanted whole cell, formalised suspension containing Moritella viscosa, were protected against subsequent challenge, achieving an RPS of 97 % (Greger and
Goodrich 1999 ). A multivalent (containing antigens to 5 pathogens) oil-adjuvanted
vaccine, which contained Moritella viscosa antigens, did not induce protection in
turbot, but did lead to some intra-abdominal adhesions (Björnsdóttir et al. 2004 ).
Subsequent work demonstrated that the protective antigens included lipooligosaccharides and a ~17–19 kDa outer membrane antigen, which induced antibody
response in vaccinated fi sh (Heidarsdöttir et al. 2008 ). A ~20 kDa OMP (= MvOMP1)
has been also regarded as the major protective antigen, raising the possibility of its
use in a future subunit vaccine (Björnsson et al. 2011 ).
Antimicrobial Compounds Florfenicol should work, with in vitro and in vivo
experiments being seemingly successful. Plasma concentration of 3.0 ± 1.8 mg/ml
were recorded in Atlantic salmon after the administration of suitably medicated
feed. However, mortality patterns after infection were less convincing (Coyne et al.
2006 ).
Mycoplasmataceae Representative
Mycoplasma mobile
Cell wall defective/defi cient bacteria, i.e. L-forms and mycoplasmas, have been
recently associated with fi sh diseases. Since the initial recovery of a motile mycoplasma from fi sh (Kirchhoff and Rosengarten 1984 ), a new species, i.e. Mycoplasma
mobile, has been described (Kirchhoff et al. 1987 ). In addition, there is an increasing awareness of L-forms in fi sh diseases. To date, L-forms have been described for
Aer. salmonicida and Y. ruckeri (McIntosh and Austin 1990 ). Both L-forms and
mycoplasmas are osmotically fragile organisms without cell walls, requiring specialized procedures for their recovery and growth.
Characteristics of the Disease
The mycoplasma was associated with “red disease”, a condition in the gills of tench
( Tinca tinca) (Kirchhoff et al. 1987 ).
11 Miscellaneous Pathogens
Disease Control
Vaccine Development Atlantic salmon, which were vaccinated i.p. with an adjuvanted whole cell, formalised suspension containing Moritella viscosa, were protected against subsequent challenge, achieving an RPS of 97 % (Greger and
Goodrich 1999 ). A multivalent (containing antigens to 5 pathogens) oil-adjuvanted
vaccine, which contained Moritella viscosa antigens, did not induce protection in
turbot, but did lead to some intra-abdominal adhesions (Björnsdóttir et al. 2004 ).
Subsequent work demonstrated that the protective antigens included lipooligosaccharides and a ~17–19 kDa outer membrane antigen, which induced antibody
response in vaccinated fi sh (Heidarsdöttir et al. 2008 ). A ~20 kDa OMP (= MvOMP1)
has been also regarded as the major protective antigen, raising the possibility of its
use in a future subunit vaccine (Björnsson et al. 2011 ).
Antimicrobial Compounds Florfenicol should work, with in vitro and in vivo
experiments being seemingly successful. Plasma concentration of 3.0 ± 1.8 mg/ml
were recorded in Atlantic salmon after the administration of suitably medicated
feed. However, mortality patterns after infection were less convincing (Coyne et al.
2006 ).
Mycoplasmataceae Representative
Mycoplasma mobile
Cell wall defective/defi cient bacteria, i.e. L-forms and mycoplasmas, have been
recently associated with fi sh diseases. Since the initial recovery of a motile mycoplasma from fi sh (Kirchhoff and Rosengarten 1984 ), a new species, i.e. Mycoplasma
mobile, has been described (Kirchhoff et al. 1987 ). In addition, there is an increasing awareness of L-forms in fi sh diseases. To date, L-forms have been described for
Aer. salmonicida and Y. ruckeri (McIntosh and Austin 1990 ). Both L-forms and
mycoplasmas are osmotically fragile organisms without cell walls, requiring specialized procedures for their recovery and growth.
Characteristics of the Disease
The mycoplasma was associated with “red disease”, a condition in the gills of tench
( Tinca tinca) (Kirchhoff et al. 1987 ).
11 Miscellaneous Pathogens